Sernova Biotherapeutics

#Type 1 Diabetes #Regenerative Medicine #Hypothyroidism #Hemophilia A

Regenerative medicine company developing the Cell Pouch Bio-Hybrid Organ platform — an implantable, retrievable, pre-vascularized cell containment system for type 1 diabetes, hypothyroidism, and hemophilia A.

Company Info

Sector:Devices - Implants

Headquarters:London, Ontario, Canada

Founded:2003

Website:sernova.com/

Upcoming Milestones & Key Dates

2026-09-08

Corporate

Merger with Seraxis announced

Clinical Development Pipeline

Cell Pouch Bio-Hybrid Organ

Target: Islet transplantation

Type 1 Diabetes

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cell Pouch (iPSC)

Target: iPSC islets (Evotec partnership)

Type 1 Diabetes (iPSC-derived)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Jonathan Rigby

President & CEO

Careers & Job Openings

See all open roles

Various

London, Ontario / Boston

Apply Now →